30 results on '"Wang, Tianfeng"'
Search Results
2. Clinical phenotypes combined with saturation genome editing identifying the pathogenicity of BRCA1 variants of uncertain significance in breast cancer
- Author
-
Wan, Qiting, Hu, Li, Ouyang, Tao, Li, Jinfeng, Wang, Tianfeng, Fan, Zhaoqing, Fan, Tie, Lin, Benyao, Xu, Ye, and Xie, Yuntao
- Published
- 2021
- Full Text
- View/download PDF
3. Comparisons of breast conserving therapy versus mastectomy in young and old women with early-stage breast cancer: long-term results using propensity score adjustment method
- Author
-
Wang, Lize, He, Yingjian, Li, Jinfeng, Wang, Tianfeng, Xie, Yuntao, Fan, Zhaoqing, and Ouyang, Tao
- Published
- 2020
- Full Text
- View/download PDF
4. Spectrum and clinical relevance of PALB2 germline mutations in 7657 Chinese BRCA1/2-negative breast cancer patients
- Author
-
Wu, Yifan, Ouyang, Tao, Li, Jinfeng, Wang, Tianfeng, Fan, Zhaoqing, Fan, Tie, Lin, Benyao, Xu, Ye, and Xie, Yuntao
- Published
- 2020
- Full Text
- View/download PDF
5. Efficacy of pegfilgrastim to support neoadjuvant dose-dense epirubicin and cyclophosphamide chemotherapy in breast cancer
- Author
-
Wang, Xinguang, He, Yingjian, Wang, Tianfeng, Xie, Yuntao, Li, Jinfeng, Ouyang, Tao, and Fan, Zhaoqing
- Published
- 2019
- Full Text
- View/download PDF
6. Risk of ipsilateral breast tumor recurrence in primary invasive breast cancer following breast-conserving surgery with BRCA1 and BRCA2 mutation in China
- Author
-
Cao, Wei, Xie, Yuntao, He, Yingjian, Li, Jinfeng, Wang, Tianfeng, Fan, Zhaoqing, Fan, Tie, and Ouyang, Tao
- Published
- 2019
- Full Text
- View/download PDF
7. Co-mutation of TP53 and PIK3CA in residual disease after neoadjuvant chemotherapy is associated with poor survival in breast cancer
- Author
-
Chen, Xinyi, Guo, Yonghai, Ouyang, Tao, Li, Jinfeng, Wang, Tianfeng, Fan, Zhaoqing, Fan, Tie, Lin, Benyao, Xu, Ye, and Xie, Yuntao
- Published
- 2019
- Full Text
- View/download PDF
8. Prevalence and characterization of ATM germline mutations in Chinese BRCA1/2-negative breast cancer patients
- Author
-
Yang, Ziguo, Ouyang, Tao, Li, Jinfeng, Wang, Tianfeng, Fan, Zhaoqing, Fan, Tie, Lin, Benyao, Zhang, Juan, and Xie, Yuntao
- Published
- 2019
- Full Text
- View/download PDF
9. Identification and analysis of CHEK2 germline mutations in Chinese BRCA1/2-negative breast cancer patients
- Author
-
Fan, Zhenhua, Ouyang, Tao, Li, Jinfeng, Wang, Tianfeng, Fan, Zhaoqing, Fan, Tie, Lin, Benyao, Xu, Ye, and Xie, Yuntao
- Published
- 2018
- Full Text
- View/download PDF
10. 99mTc-rituximab as a tracer for sentinel lymph node biopsy in breast cancer patients: a single-center analysis
- Author
-
Wang, Jiwei, Fan, Tie, He, Yingjian, Chen, Xue, Fan, Zhaoqing, Xie, Yuntao, Wang, Tianfeng, Li, Jinfeng, and Ouyang, Tao
- Published
- 2018
- Full Text
- View/download PDF
11. Low expression of RECQL is associated with poor prognosis in Chinese breast cancer patients
- Author
-
Xu, Huiying, Xu, Ye, Ouyang, Tao, Li, Jinfeng, Wang, Tianfeng, Fan, Zhaoqing, Fan, Tie, Lin, Benyao, and Xie, Yuntao
- Published
- 2018
- Full Text
- View/download PDF
12. Comprehensive analysis of BRCA1 and BRCA2 germline mutations in a large cohort of 5931 Chinese women with breast cancer
- Author
-
Zhang, Juan, Sun, Jie, Chen, Jiuan, Yao, Lu, Ouyang, Tao, Li, Jinfeng, Wang, Tianfeng, Fan, Zhaoqing, Fan, Tie, Lin, Benyao, and Xie, Yuntao
- Published
- 2016
- Full Text
- View/download PDF
13. A single-center, randomized, parallel controlled study comparing the efficacy and safety aspects of three anthracycline-based regimens as neoadjuvant chemotherapy in primary breast cancer
- Author
-
Zhou, Yijun, Ouyang, Tao, Xie, Yuntao, Wang, Tianfeng, Fan, Zhaoqing, He, Yingjian, Lu, Aiping, Liu, Yiqiang, and Li, Jinfeng
- Published
- 2016
- Full Text
- View/download PDF
14. Impact of Sentinel Lymph Node Biopsy on Treatment Decision and Survival in Patients Aged ≥70 Years with Breast Cancer: A Retrospective Study.
- Author
-
Gu, Chongshan, Chen, Xue, Wang, Lize, He, Yingjian, Ouyang, Tao, Li, Jinfeng, Wang, Tianfeng, Fan, Tie, and Fan, Zhaoqing
- Subjects
SENTINEL lymph node biopsy ,SENTINEL lymph nodes ,OVERALL survival ,OLDER patients ,BREAST cancer ,LYMPH node cancer ,PROGESTERONE receptors - Abstract
Background: Whether sentinel lymph node biopsy should be performed in patients ≥70 years old with early-stage invasive breast cancer is controversial. We examined the effect of sentinel lymph node biopsy on the treatment and outcomes in this population. Materials and Methods: In this retrospective study, patients aged ≥70 years who were treated for invasive breast cancer with sentinel lymph node biopsy followed by mastectomy or lumpectomy between 2010 and 2019 were identified from our database. Patients were compared according to sentinel lymph node status. Outcomes were analyzed using the Kaplan–Meier method and Cox multivariate analysis. Results: Of the 376 patients enrolled in this study, 311 (82.7%) were sentinel lymph node-negative and 65 (17.3%) were sentinel lymph node-positive. The median follow-up duration for all patients was 70 months. Systemic treatment and radiation were similar between sentinel lymph node-negative and -positive groups. Disease-free survival, distant disease-free survival, breast cancer-specific survival, overall survival were not significantly different between groups (88.2% vs 87.6%, 96.7% vs 94.8%, 96.2% vs 93.6%, and 93.5% vs 90.0%, respectively). Sentinel lymph node status, tumor size, chemotherapy, endocrine therapy, and adjuvant radiation were included in Cox multivariate analysis. None of the variables were found to significantly affect disease-free survival, distant disease-free survival, breast cancer-specific survival, and overall survival. Conclusions: Our analysis indicated that sentinel lymph node status may not affect systemic treatment decisions or survival in patients aged ≥70 years with breast cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
15. Risk of ipsilateral breast tumor recurrence and contralateral breast cancer in patients with and without TP53 variant in a large series of breast cancer patients.
- Author
-
Guo, Yonghai, Wan, Qiting, Ouyang, Tao, Li, Jinfeng, Wang, Tianfeng, Fan, Zhaoqing, and Xie, Yuntao
- Subjects
BREAST cancer ,CANCER patients ,DISEASE relapse ,BREAST tumors ,CANCER relapse ,CANCER hospitals - Abstract
The association between breast cancer patients with a TP53 pathogenic variant and risk of local recurrence and contralateral breast cancer remains largely unknown. The study population of 11093 patients was derived from two cohorts at the Breast Center of Peking University Cancer Hospital in China from November 2003, to March 2018. TP53 germline variants were determined for all patients. In the study, forty-one (0.37%) carried a TP53 germline pathogenic variant, and 11052 were non-carriers (99.63%). Nineteen TP53 carriers (46.3%) and 4173 non-carriers (37.8%) were treated with breast-conserving therapy (BCT), while the remaining were treated with mastectomy. After a median follow-up of 6.7 years, the rate of ipsilateral breast tumor recurrence (IBTR) in TP53 carriers was significantly higher than that in non-carriers when treated with BCT (21.1% vs 3.8%, P = 0.006). No difference in the rate of IBTR was found between TP53 carriers and non-carriers when treated with mastectomy (0.0% vs 2.6%, P = 1.0). Furthermore, the rate of IBTR in TP53 carriers treated with BCT was significantly higher than that in those treated with mastectomy (21.1% vs 0.0%, P = 0.038). The 10-year cumulative risk of contralateral breast cancer in TP53 carriers was significantly higher than that in non-carriers (17.9% vs 3.6%, hazard ratio (HR) = 7.0, 95% CI: 3.3–14.9, P < 0.001). Patients with TP53 variants have a high risk of IBTR when treated with BCT, and exhibit a very high risk of contralateral breast cancer. TP53 carriers may not be suitable for BCT and prophylactic contralateral mastectomy might be considered. • Patients with a TP53 variant have a high risk of IBTR when treated with BCT. • TP53 carriers exhibit a very high risk of contralateral breast cancer. • TP53 carriers may not be suitable for BCT. • Prophylactic contralateral mastectomy may be considered for TP53 carriers. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
16. Impact of the addition of carboplatin to anthracycline‐taxane‐based neoadjuvant chemotherapy on survival in BRCA1/2‐mutated triple‐negative breast cancer.
- Author
-
Zhang, Juan, Yao, Lu, Liu, Yiqiang, Ouyang, Tao, Li, Jinfeng, Wang, Tianfeng, Fan, Zhaoqing, Fan, Tie, Lin, Benyao, and Xie, Yuntao
- Subjects
TRIPLE-negative breast cancer ,NEOADJUVANT chemotherapy ,CARBOPLATIN ,BREAST cancer ,CANCER patients - Abstract
Whether adding carboplatin to standard neoadjuvant chemotherapy improves survival in BRCA1/2‐mutated triple‐negative breast cancer (TNBC) is unknown. In this retrospective study, we aimed to explore the efficacy of anthracycline‐taxane (A‐T)‐based or anthracycline‐taxane/carboplatin (A‐TP)‐based neoadjuvant chemotherapy in BRCA1/2‐mutated TNBC. A total of 1585 operable primary breast cancer patients were treated with either neoadjuvant A‐T (n = 886) or A‐TP regimen (n = 699). BRCA1 and BRCA2 germline mutations were determined in all subjects. Pathological complete response (pCR), recurrence‐free survival (RFS), distant recurrence‐free survival (DRFS) and overall survival (OS) were estimated. Of the entire cohort, 102 patients (6.4%) carried a pathogenic BRCA1/2 germline mutation. After a median follow‐up of 81 months, no significant differences in survival between the A‐T and A‐TP arms were found in the entire cohort. However, among 288 TNBC patients, BRCA1/2 mutation carriers had significantly better survival when treated with the A‐TP regimen than with the A‐T regimen (5‐year RFS: 82.6% vs 47.9%; P =.024; 5‐year DRFS: 88.5% vs 46.9%; P =.010; 5‐year OS: 88.2% vs 49.9%; P =.036). Multivariate analyses revealed that the A‐TP regimen was a significantly favourable factor for RFS and DRFS and showed a trend towards better OS when compared with the A‐T regimen in BRCA1/2‐mutated TNBC (RFS: adjusted hazard ratio [HR], 0.24; 95% confidence interval [CI], 0.06‐0.91, P =.035; DRFS: HR, 0.17; 95% CI, 0.03‐0.80; P =.025; OS: HR, 0.29; 95% CI, 0.06‐1.49; P =.14). Our study suggested that BRCA1/2‐mutated TNBC patients gain a survival benefit when carboplatin is added to standard A‐T‐based neoadjuvant chemotherapy. What's new? Due to their deficiency in DNA‐repair capacity, BRCA1/2 mutation carriers might be sensitive to platinum agents. Whether adding carboplatin to standard neoadjuvant chemotherapy improves survival in BRCA1/2‐mutated triple‐negative breast cancer however remains unknown. In this retrospective study, 1585 operable primary breast cancer patients were treated with either an anthracycline followed by taxane (A‐T) or an anthracycline followed by taxane plus carboplatin (A‐TP) neoadjuvant regimen. No significant differences in survival between the A‐T and A‐TP arms were found in the entire cohort. However, BRCA1/2‐mutated triple‐negative breast cancer patients showed significantly better survival with the A‐TP regimen than with the A‐T regimen. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
17. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers in a large cohort of unselected Chinese breast cancer patients.
- Author
-
Su, Liming, Xu, Ye, Ouyang, Tao, Li, Jinfeng, Wang, Tianfeng, Fan, Zhaoqing, Fan, Tie, Lin, Benyao, and Xie, Yuntao
- Subjects
BREAST cancer ,BRCA genes ,CANCER patients ,FAMILY history (Medicine) ,CANCER diagnosis - Abstract
To estimate the cumulative risk of contralateral breast cancer (CBC) in BRCA1/2 carriers in a large cohort of unselected Chinese breast cancer patients. Our study comprised 9,401 unselected Chinese breast cancer patients and BRCA1/2 germline mutations were determined in all patients. After a median follow‐up of 5.7 years, 181 patients developed CBC in this cohort. Compared to noncarriers, BRCA1 and BRCA2 carriers had a 4.52‐fold (95% CI, 2.63–7.76) and 5.54‐fold (95% CI, 3.51–8.74) increased risk of CBC, respectively. The 10‐year cumulative risk of CBC was 15.5% (95% CI, 9.9–24.2) for BRCA1 carriers, 17.5% (95% CI, 10.9–28.0) for BRCA2 carriers and 3.2% (95% CI, 2.5–4.1) for noncarriers. Younger age at first breast cancer diagnosis was significantly associated with an increased 10‐year risk of CBC for BRCA1 carriers (≤40 years vs. >40 years: 21.5% vs. 11.9%, unadjusted hazard ratio [HR] = 2.51, 95% CI, 1.03–6.15, p = 0.044), but not for BRCA2 carriers and noncarriers. The 10‐year cumulative CBC risk was significantly higher in both BRCA1 and BRCA2 carriers who had a family history of breast cancer than in those who did not (BRCA1: 27.5% vs. 9.4%, adjusted HR = 2.64, 95% CI, 1.01–6.97, p = 0.049; BRCA2: 27.1% vs. 12.8%, adjusted HR = 2.29, 95% CI, 1.04–5.06, p = 0.040). In conclusion, the risk of CBC was a substantial high in BRCA1/2 carriers in unselected Chinese breast cancer patients, and CBC risk is much more remarkable in both BRCA1 and BRCA2 carriers who had a family history of breast cancer. Younger age at first breast cancer diagnosis also enhanced CBC risk in BRCA1 carriers. What's new? While germline mutations in the BRCA 1 and BRCA2 genes raise contralateral breast cancer (CBC) risk in women, the influence of these mutations on CBC risk varies among ethnic populations. This study examined CBC risks in BRCA1/2 mutation carriers specifically in a cohort of unselected Chinese breast cancer patients. Cumulative CBC risk was significantly increased for BRCA1/2 mutation carriers, especially those with family history of the disease. Risks were lower relative to Caucasian and Jewish cohorts, possibly because, unlike previous analyses, the authors of the present study did not recruit BRCA1/2 mutation carriers based on family history of breast cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
18. BRCA1 c.5470_5477del, a founder mutation in Chinese Han breast cancer patients.
- Author
-
Meng, Hua, Yao, Lu, Yuan, Hua, Xu, Ye, Ouyang, Tao, Li, Jinfeng, Wang, Tianfeng, Fan, Zhaoqing, Fan, Tie, Lin, Benyao, and Xie, Yuntao
- Subjects
BREAST cancer ,CHINESE people ,CANCER patients ,FREQUENCY spectra ,GENETIC mutation - Abstract
The spectrum and frequency of BRCA1/2 pathogenic variants may be ethnicity‐specific. Whether high‐frequency founder mutations are present in Chinese women remains largely unknown. In the current study, germline pathogenic variants in the BRCA1/2 genes were determined in 9,505 unselected Chinese Han breast cancer (BC) patients by next‐generation and/ or Sanger sequencing. Four hundred and seventy‐one (5.0%) BC patients carried BRCA1/2 pathogenic variants in this cohort. A total of 25 recurrent pathogenic variants (at least found in four unrelated patients) were identified in this cohort (8 BRCA1 and 17 BRCA2 recurrent pathogenic variants), 161 patients carried one of these recurrent pathogenic variants in this cohort of 9,505 patients. All of these 25 recurrent pathogenic variants were further explored whether they had founder effect through haplotype analysis. The most common pathogenic variant, BRCA1 c.5470_5477del, was found in 30 BC patients from 29 unrelated families. Twenty‐seven of these 29 unrelated patients who carried this BRCA1 c.5470_5477del mutation shared an identical haplotype, indicating that BRCA1 c.5470_5477del was a founder mutation in the Chinese Han population. Furthermore, BRCA1 c.5470_5477del mutation carriers had a significantly worse survival than noncarriers (disease‐free survival, p = 0.049; overall survival, p = 0.029). Taken together, our data suggested that BRCA1 c.5470_5477del is a founder mutation in the Chinese Han population and BRCA1 c.5470_5477del mutation carriers have a poor survival. What's new? Founder mutations in the BRCA1/2 genes are mostly defined in Caucasian populations while other ethnicities remain understudied. Here the authors studied a new gene variant in almost 10,000 Chinese Han women with breast cancer. The BRCA1 c.5470_5477del variant was found in 0.3% of the women in the study, most of them sharing the same haplotype, suggesting that it functions as a new founder mutation in this ethnic population. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
19. Prevalence and clinical impact of TP53 germline mutations in Chinese women with breast cancer.
- Author
-
Sheng, Shuyan, Xu, Ye, Guo, Yonghai, Yao, Lu, Hu, Li, Ouyang, Tao, Li, Jinfeng, Wang, Tianfeng, Fan, Zhaoqing, Fan, Tie, Lin, Benyao, and Xie, Yuntao
- Subjects
BREAST cancer ,CANCER chemotherapy ,SUPPRESSOR mutation ,RECTAL cancer ,DISEASE prevalence - Abstract
The prevalence and clinical relevance of TP53 germline mutations in a large unselected breast cancer series are largely unknown. Here, we determined TP53 germline mutations in a large cohort of 10,053 unselected breast cancer patients through multigene panel‐based next‐generation and/or Sanger sequencing assays. We found that 0.5% of patients (50 cases) carried a pathogenic TP53 germline mutation in this large series of 10,053 unselected breast cancer patients, and the prevalence of TP53 germline mutation was 3.8% in very early onset breast cancer (age ≤30 years) in this large cohort. TP53 mutation carriers were significantly more likely to have early onset cancer (p < 0.001) and bilateral breast cancer (p = 0.03), they and were significantly more likely to respond to carboplatin‐based neoadjuvant chemotherapy compared to anthracycline‐ or taxane‐based regimen in terms of pathologic complete response (50% vs. 0%, p = 0.006). At the median follow‐up of 54 months, TP53 mutation was an independent unfavorable factor for recurrence‐free survival (RFS), distant recurrence‐free survival (DRFS), and overall survival (OS) (RFS, adjusted hazard ratio [HR]: 2.24, 95% confidence interval [CI]: 1.15–4.33, p = 0.02; DRFS, adjusted HR: 2.73, 95% CI: 1.41–5.30, p = 0.003; OS, adjusted HR: 4.60, 95% CI: 2.26–9.41, p < 0.001) in multivariate analyses. Our study suggested that TP53 germline mutations occur more frequently in very early onset unselected breast cancer patients; and TP53 germline mutation carriers have a very poor survival and may benefit from carboplatin‐based neoadjuvant chemotherapy in unselected breast cancer patients. What's new? Carriers of germline mutations of the tumor suppressor TP53 have a 100‐times higher risk to develop cancer, often in multiple organs, but the clinical relevance of the mutations in women with breast cancer remains unclear. Here, the authors examined more than 10,000 Chinese women with breast cancer and found 0.5% (50 cases) carried a pathogenic TP53 germline mutation. Carriers more often had early‐onset disease, a poorer survival and responded to carboplatin‐based neoadjuvant chemotherapy, the latter a relevant therapeutic outcome of testing for mutation carriers. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
20. Ultrasound as a replacement for physical examination in clinical staging of axillary lymph nodes in breast cancer patients.
- Author
-
Chen, Xue, Li, Xiaoting, Fan, Zhaoqing, Li, Jinfeng, Xie, Yuntao, Wang, Tianfeng, and Ouyang, Tao
- Subjects
BREAST tumors ,CANCER patients ,CHI-squared test ,LYMPH nodes ,PHYSICAL diagnosis ,DATA analysis - Abstract
Background: The status of axillary lymph nodes (ALNs) is one of the important factors in decision‐making for breast cancer treatment. Physical examination (PE) has long been the main, or even the only, means of clinical staging for ALNs in breast cancer. However, the sensitivity and accuracy of PE remains unsatisfactory. The results from this study suggest that axillary ultrasonography (US) should replace PE as a standard method for the clinical staging of ALNs in breast cancer. Methods: Consecutive and nonselective breast cancer patients treated between September 2018 and November 2018 in our center were enrolled in the study. Comparisons of ALN results between PE/US and pathological results were conducted and the difference in sensitivity, specificity and accuracy between PE and US were tested by McNemar chi‐square test. Results: A total of 123 patients were enrolled into the study. Their ages ranged from 28 to 76 years with a median age of 53 ± 10. There were 83 ALN positive cases and 40 ALN negative cases confirmed pathologically. The sensitivity, specificity, accuracy, positive predictive value and negative predictive value of PE and US were 54.2%, 90.0%, 65.9%, 91.8%, 48.7% versus 86.8%, 72.5%, 82.1%, 86.8%, 72.5%, respectively. The sensitivity and accuracy of US was significantly higher than that of PE (P = 0.004 and P = 0.002). Conclusion: The results of this study demonstrated that US is superior in evaluating ALNs when compared with PE and that US should replace PE as the standard method for the clinical staging of ALNs in breast cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
21. Germline mutation in DNA‐repair genes is associated with poor survival in BRCA1/2‐negative breast cancer patients.
- Author
-
Fan, Zhenhua, Hu, Li, Ouyang, Tao, Li, Jinfeng, Wang, Tianfeng, Fan, Zhaoqing, Fan, Tie, Lin, Benyao, Xu, Ye, and Xie, Yuntao
- Abstract
BRCA1/2 genes are the most frequently germline mutated DNA‐repair genes, and the survival of BRCA1/2 carriers has been extensively explored in breast cancer. However, the prevalence of germline mutations in non‐BRCA1/2 DNA‐repair genes and the survival of carriers are largely unknown in a large cohort of unselected breast cancer patients. Germline mutations in 16 DNA‐repair genes were determined using a multigene panel in 7657 BRCA1/2‐negative breast cancer patients who were unselected for family history of cancer or age at diagnosis. Among the 7657 BRCA1/2‐negative breast cancer patients, 257 (3.4%) carried at least 1 pathogenic germline mutation in the 16 DNA‐repair genes. The prevalence of DNA‐repair gene mutations was significantly higher in familial breast cancers (5.2%, P = 0.002) and early‐onset breast cancers (diagnosed at and before the age of 40) (4.5%, P = 0.003) than that of sporadic breast cancers (2.9%) (diagnosed above age of 40), respectively. The DNA‐repair gene mutation carriers were significantly more likely to have a larger tumor (P = 0.04) and axillary lymph node metastasis (P = 0.03). Moreover, DNA‐repair gene mutation was an independent unfavorable factor for recurrence‐free survival (adjusted hazard ratio [HR] = 1.38, 95% CI: 1.00‐1.91, P = 0.05) and disease‐specific survival (adjusted HR=1.63, 95% CI: 1.04‐2.57, P = 0.03) in this cohort. Overall, 3.4% of BRCA1/2‐negative breast cancer patients carried germline mutations in the 16 DNA‐repair genes, and the DNA‐repair gene mutation carriers exhibited an aggressive phenotype and had poor survival compared with noncarriers. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
22. RAD50 germline mutations are associated with poor survival in BRCA1/2–negative breast cancer patients.
- Author
-
Fan, Cong, Zhang, Juan, Ouyang, Tao, Li, Jinfeng, Wang, Tianfeng, Fan, Zhaoqing, Fan, Tie, Lin, Benyao, and Xie, Yuntao
- Abstract
RAD50 is a highly conserved DNA double‐strand break (DSB) repair gene. However, the associations between RAD50 germline mutations and the survival and risk of breast cancer have not been fully elucidated. Here, we aimed to investigate the clinical impact of RAD50 germline mutations in a large cohort of unselected breast cancer patients. In our study, RAD50 germline mutations were determined using next‐generation sequencing in 7657 consecutive unselected breast cancer patients without BRCA1/2 mutations. We also screened for RAD50 recurrent mutations (L719fs, K994fs, and H1269fs) in 5000 healthy controls using Sanger sequencing. We found that 26 out of 7,657 (0.34%) patients had RAD50 pathogenic mutations, and 16 patients carried one of the three recurrent mutations (L719fs, n = 6 cases; K994fs, n = 5 cases; and H1269fs, n = 5 cases); the recurrent mutation rate was 0.21%. The frequency of the three recurrent mutations in the 5,000 healthy controls was 0.18% (9/5,000). These mutations did not confer an increased risk of breast cancer in the studied patients [odds ratios (OR), 1.16; 95% confidence interval (CI), 0.51–2.63; p = 0.72]. Nevertheless, multivariate analysis revealed that RAD50 pathogenic mutations were an independent unfavourable predictor of recurrence‐free survival (RFS) [adjusted hazard ratio (HR) 2.66; 95% CI, 1.18–5.98; p = 0.018] and disease‐specific survival (DSS; adjusted HR 4.36; 95% CI, 1.58–12.03; p = 0.004) in the entire study cohort. Our study suggested that RAD50 germline mutations are not associated with an increased risk of breast cancer, but patients with RAD50 germline mutations have unfavourable survival compared to patients without these mutations. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
23. Association between HER2 germline mutation A270S and prognosis in patients with primary breast cancer.
- Author
-
Si, Pilei, Xu, Ye, Ouyang, Tao, Li, Jinfeng, Wang, Tianfeng, Fan, Zhaoqing, Fan, Tie, Lin, Benyao, and Xie, Yuntao
- Subjects
GERM cells ,PROGNOSIS ,KAPLAN-Meier estimator ,PROGRESSION-free survival ,GENETIC mutation - Abstract
PURPOSE: To investigate the association between the HER2 germline mutation Ala270Ser (A270S), located in HER2 extracellular domain, and survival in breast cancer patients. METHODS: HER2 germline mutation A270S was identified in 5395 consecutive patients with operable primary breast cancer using direct Sanger sequencing analysis. Survival curves for patients with HER2 A270S mutation were compared using the Kaplan-Meier method with log-rank test. RESULTS: We identified that 31 cases carried HER2 germline mutation A270S in 5395 patients (0.6%, 31/5395). The HER2 A270S mutation was significantly associated with recurrence-free survival (RFS) and distant recurrence-free survival (DRFS) in the entire cohort of 5395 patients (RFS, unadjusted hazard ratio [HR] = 2.23; 95% confidence interval [CI] = 1.00–5.00; P = 0.045; DRFS, unadjusted HR = 2.80; 95% CI = 1.25–6.28; P = 0.009). Among the HER2-negative patients (n = 3825), those with the HER2 A270S mutation had a significantly worse RFS (unadjusted HR = 3.19; 95% CI = 1.42–7.16; P = 0.003) and DRFS (unadjusted HR = 3.98; 95% CI = 1.77–8.96; P < 0.001) than did those with wild type. Moreover, the A270S mutation remained an independent unfavorable factor for RFS and DRFS in the HER2-negative patients (RFS, HR = 3.30; 95% CI = 1.34–8.10; P = 0.009; DRFS, HR = 4.26; 95% CI = 1.73–10.47; P = 0.002). CONCLUSIONS: Breast cancer patients with the HER2 germline mutation A270S had a worse survival, especially in HER2-negative patients. Therefore, HER2-negative patients with a HER2 germline mutation A270S might be potential candidates for HER2-targeted therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
24. Feasibility of using negative ultrasonography results of axillary lymph nodes to predict sentinel lymph node metastasis in breast cancer patients.
- Author
-
Chen, Xue, He, Yingjian, Wang, Jiwei, Huo, Ling, Fan, Zhaoqing, Li, Jinfeng, Xie, Yuntao, Wang, Tianfeng, and Ouyang, Tao
- Subjects
BREAST cancer patients ,SENTINEL lymph nodes ,ULTRASONIC imaging of cancer ,MEDICAL databases ,MEDICAL centers ,CANCER - Abstract
Abstract: Knowledge of the pathology of axillary lymph nodes (ALN) in breast cancer patients is critical for determining their treatment. Ultrasound is the best noninvasive evaluation for the ALN status. However, the correlation between negative ultrasound results and the sentinel lymph nodes (SLN) pathology remains unknown. To test the hypothesis that negative ultrasound results of ALN predict the negative pathology results of SLN in breast cancer patients, we assessed the association between ALN ultrasonography‐negative results and the SLN pathology in 3115 patients with breast cancer recruited between October 2010 and April 2016 from a single cancer center, prospective database. Of these patients who met the inclusion criteria, 2317 (74.4%) had no SLN pathological metastasis. In the univariate analysis, other 798 patient with positive SLN tended to be under age 40 and premenopausal, having large tumor sizes (>2 cm), higher histological grade of primary tumor, positive hormone receptors, and negative HER‐2 status (P < .05 for all). In the multivariate analysis, menstrual status, tumor size, ER status and histological types of primary tumor remained to be independent predictors for SLN pathological metastasis. The area under curve (AUC) was 0.658 (95% CI = 0.637‐0.679), P > .05. In conclusion, only a 74.4% consistency between ALN ultrasonography‐negative results and negative pathological SLN results, although menstrual status, tumor size, histologic subtypes of primary tumor and ER status were found to be statistically independent predictors of positive SLN among patients negative for ALN ultrasonography. Therefore, the present study suggests that negative ultrasound results of ALN do not adequately predict the negative pathology results of SLN in breast cancer patients. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
25. Identification and analysis of <italic>CHEK2</italic> germline mutations in Chinese <italic>BRCA1/2</italic>-negative breast cancer patients.
- Author
-
Fan, Zhenhua, Ouyang, Tao, Li, Jinfeng, Wang, Tianfeng, Fan, Zhaoqing, Fan, Tie, Lin, Benyao, Xu, Ye, and Xie, Yuntao
- Abstract
Purpose: Cell-cycle-checkpoint kinase 2 (
CHEK2 ) is an important moderate-penetrance breast cancer predisposition gene; however, recurrentCHEK2 mutations found in Caucasian women are very rare in Chinese population. We investigated the mutation spectrum and clinical relevance ofCHEK2 germline mutations in Chinese breast cancer patients.Methods: The entire coding regions and splicing sites ofCHEK2 were screened in 7657 ChineseBRCA1/2 -negative breast cancer patients, using 62-gene panel-based sequencing.Results: Out of 7657BRCA1/2 -negative breast cancer patients, 26 (0.34%) carriedCHEK2 pathogenic germline mutations. Most of these mutations (92.3%, 24/26) were nonsense or frameshift mutations; 84.6% (22/26) of them were in forkhead-associated (FHA) or kinase domains. Of the 18 types ofCHEK2 mutations we found, 61.1% (11/18) of were novel mutations and two recurrent mutations (Y139X and R137X) were found in this cohort. Patients withCHEK2 mutations were significantly more likely to have family histories of breast and/or ovarian cancer (23.1% vs. 8.6%,p = 0.022) and family histories of any cancer (50.0% vs. 31.6%,p = 0.044); and were significantly more likely to have lymph node-positive (53.8% vs. 27.3%,p = 0.002) and progesterone receptor (PR)-positive (88.5% vs. 64.5%,p = 0.011) breast cancers.Conclusions: Among Chinese breast cancer patients, theCHEK2 germline mutation rate is approximately 0.34% and two specific mutations (Y139X and R137X) are recurrent. Patients withCHEK2 mutations are significantly more likely to have family histories of cancer, and to develop lymph node-positive and/or PR-positive breast cancers. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
26. 99mTc-rituximab as a tracer for sentinel lymph node biopsy in breast cancer patients: a single-center analysis.
- Author
-
Wang, Jiwei, Fan, Tie, He, Yingjian, Chen, Xue, Fan, Zhaoqing, Xie, Yuntao, Wang, Tianfeng, Li, Jinfeng, and Ouyang, Tao
- Abstract
Purpose: This study aimed to determine the long-term prognosis of breast cancer patients with
99m Tc-rituximab for sentinel lymph node biopsy (SLNB).Methods: A total of 2947 patients with negative sentinel lymph nodes (SLNs) omitting axillary lymph node dissection (ALND), treated between June 2005 and December 2013, were retrospectively analyzed. SLNB was performed prior to adjuvant therapy.Results: After a median follow-up of 62 months, 22 cases of axillary recurrence (AR) were observed. The 5-year AR rate (ARR) was 0.7% [95% confidence interval (CI) 0.3-1.1%] and the 5-year relapse-free survival (RFS) was 95.2% (95% CI 94.4-96.0%). Multivariate analysis showed that abnormal axillary ultrasound with negative fine-needle aspiration (FNA) [hazard ratio (HR) 3.79, 95% CI 1.55-9.28;P = 0.004], not receiving radiotherapy (HR 4.38, 95% CI 1.47-13.05;P = 0.008), and age ≤ 40 years (HR 2.93, 95% CI 1.19-7.20;P = 0.020) were independent risk factors for AR.Conclusions: ARR of SLNB-negative patients with99m Tc-rituximab is low. Abnormal axillary ultrasound with negative FNA, not receiving radiotherapy, and age ≤ 40 years were prognostic factors for higher ARRs. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
27. Predictive value of BRCA1/2 mRNA expression for response to neoadjuvant chemotherapy in BRCA‐negative breast cancers.
- Author
-
Xu, Ye, Ouyang, Tao, Li, Jinfeng, Wang, Tianfeng, Fan, Zhaoqing, Fan, Tie, Lin, Benyao, and Xie, Yuntao
- Abstract
It is well known that
BRCA1 andBRCA2 play a central role in DNA repair, but the relationship between BRCA1 and BRCA2 mRNA expression and response to neoadjuvant chemotherapy in sporadic breast cancer patients has not been well established. Here, we investigate the association between BRCA1 or BRCA2 mRNA expression levels and pathological response in 674 BRCA1/2 mutation‐negative breast cancer patients who received neoadjuvant chemotherapy. BRCA1 and BRCA2 mRNA expression were assessed using quantitative real‐time polymerase chain reaction in core biopsy breast cancer tissue obtained prior to the initiation of neoadjuvant chemotherapy. A total 129 patients (19.1%) achieved pathological complete response (pCR) after neoadjuvant chemotherapy. Among patients treated with anthracycline‐based chemotherapy (n = 531), BRCA1 mRNA low expression patients had a significantly higher pCR rate than intermediate or high BRCA1 mRNA expression groups (24.6% vs 16.8% or 14.0%,P = .031) and retained borderline significance (OR = 1.54, 95% CI = 0.93‐2.56,P = .094) in multivariate analysis. Among the 129 patients who received a taxane‐based regimen, pCR rate showed no differences in BRCA1 low, intermediate, and high mRNA level subgroups (19.6%, 26.8% and 21.4%, respectively;P = .71). BRCA2 mRNA level was not associated with pCR rate in the anthracyline‐based treated subgroup (P = .60) or the taxane‐based regimen subgroup (P = .82). Taken together, our findings suggested that BRCA1 mRNA expression could be used as a predictive marker in BRCA1/2 mutation‐negative breast cancer patients who received neoadjuvant anthracycline‐based treatment. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
28. HER2 somatic mutations are associated with poor survival in HER2-negative breast cancers.
- Author
-
Wang, Tonghui, Xu, Ye, Sheng, Shuyan, Yuan, Hua, Ouyang, Tao, Li, Jinfeng, Wang, Tianfeng, Fan, Zhaoqing, Fan, Tie, Lin, Benyao, and Xie, Yuntao
- Abstract
It is well documented that human epidermal growth factor receptor 2 ( HER2) overexpression/amplification is associated with poor survival in breast cancer patients. However, it is largely unknown whether HER2 somatic mutations are associated with survival in HER2-negative breast cancer patients. Here, we identified HER2 somatic mutations in tumors from 1348 unselected breast cancer patients by sequencing the entire HER2 coding region. All of these mutations were tested for in corresponding blood samples to determine whether they were somatic or germline mutations. We further investigated the associations between HER2 somatic mutations and recurrence-free survival and distant recurrence-free survival in this cohort of patients. We found that 27 of 1348 (2.0%) of these patients carried a HER2 somatic mutation. In vitro experiments indicated that some of the novel mutations and those with unknown functions increased HER2 activity. HER2 status was available for 1306 patients, and the HER2 somatic mutation rates in HER2-positive ( n = 353) and HER2-negative breast cancers ( n = 953) were 1.4% and 2.3%, respectively. Among the HER2-negative patients, those with a HER2 somatic mutation had a significantly worse recurrence-free survival (unadjusted hazard ratio = 2.67; 95% confidence interval, 1.25-5.72, P = 0.002) and distant recurrence-free survival (unadjusted hazard ratio = 2.50; 95% confidence interval, 1.10-5.68, P = 0.004) than those with wild-type HER2. Taken together, our findings suggested that HER2 somatic mutations occur at a higher frequency in HER2-negative breast cancer, and HER2-negative breast cancer patients with these mutations have poor survival. Therefore, HER2-negative patients with a HER2 somatic mutation are potentially good candidates for HER2-targeted therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
29. TP53 mutations are associated with higher rates of pathologic complete response to anthracycline/cyclophosphamide-based neoadjuvant chemotherapy in operable primary breast cancer.
- Author
-
Wang, Yuxia, Xu, Ye, Chen, Jiuan, Ouyang, Tao, Li, Jinfeng, Wang, Tianfeng, Fan, Zhaoqing, Fan, Tie, Lin, Benyao, and Xie, Yuntao
- Abstract
The role of TP53 mutations in predicting response to neoadjuvant chemotherapy in breast cancer remains controversial. The aims of this study were to investigate whether TP53 mutations were associated with response and survival in breast cancer patients who received neoadjuvant chemotherapy. Therefore, we identified TP53 mutations in the core-needle biopsy tumor samples obtained before the neoadjuvant chemotherapy from 351 operable primary breast cancer patients who either received anthracycline/cyclophosphamide-based (n=252) or paclitaxel (n=99) neoadjuvant chemotherapy. We found that 41.0% (144 of 351) of patients harbored TP53 mutations, and 14.8% of patients achieved a pCR (pathologic complete response) after neoadjuvant chemotherapy. Among patients treated with anthracycline/cyclophosphamide (n=252), patients with TP53 mutations had a significantly higher pCR rate than those with wild-type (28.6 vs.7.1%; p < 0.001), and TP53 mutation was an independent favorable predictor of pCR [odds ratio (OR)=3.41; 95% confidence interval (CI) 1.50-7.77; p=0.003] in this group; moreover, patients with TP53 mutation had a better distant recurrence-free survival (DRFS) than those with wild-type [unadjusted hazard ratio (HR)=0.43; 95% CI 0.20-0.94; p=0.030] in this group. Among patients treated with paclitaxel (n=99), no significant difference in pCR rates was observed between patients with or without TP53 mutations (15.2 vs. 11.3%; p=0.57). Our results suggested that patients with TP53 mutations are more likely to respond to anthracycline/ cyclophosphamide-based neoadjuvant chemotherapy and have a favorable survival. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
30. Mutations in RECQL Gene Are Associated with Predisposition to Breast Cancer.
- Author
-
Sun, Jie, Wang, Yuxia, Xia, Yisui, Xu, Ye, Ouyang, Tao, Li, Jinfeng, Wang, Tianfeng, Fan, Zhaoqing, Fan, Tie, Lin, Benyao, Lou, Huiqiang, and Xie, Yuntao
- Subjects
GENETIC mutation ,GENETICS ,GENES ,GENOMES ,BREAST cancer - Abstract
The genetic cause for approximately 80% of familial breast cancer patients is unknown. Here, by sequencing the entire exomes of nine early-onset familial breast cancer patients without BRCA1/2 mutations (diagnosed with breast cancer at or before the age of 35) we found that two index cases carried a potentially deleterious mutation in the RECQL gene (RecQ helicase-like; chr12p12). Recent studies suggested that RECQL is involved in DNA double-strand break repair and it plays an important role in the maintenance of genomic stability. Therefore, we further screened the RECQL gene in an additional 439 unrelated familial breast cancer patients. In total, we found three nonsense mutations leading to a truncated protein of RECQL (p.L128X, p.W172X, and p.Q266X), one mutation affecting mRNA splicing (c.395-2A>G), and five missense mutations disrupting the helicase activity of RECQL (p.A195S, p.R215Q, p.R455C, p.M458K, and p.T562I), as evaluated through an in vitro helicase assay. Taken together, 9 out of 448 BRCA-negative familial breast cancer patients carried a pathogenic mutation of the RECQL gene compared with one of the 1,588 controls (P = 9.14×10
-6 ). Our findings suggest that RECQL is a potential breast cancer susceptibility gene and that mutations in this gene contribute to familial breast cancer development. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.